Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Argenx Secures FDA Approval for Vyvgart’s New CIDP Indication, Boosting Neuro‑Immune Portfolio

FDA approves Argenx’s Vyvgart for CIDP, expanding its neuro‑immune reach and unlocking a $1B+ market with proven efficacy and a solid safety profile.

Dr. Michael Chen

11/05/2026, 15:21

3 minutes to read

Teva Executives Buy & Sell 20k+ Shares, Stock Grows Amid Routine Insider Moves

Teva insider moves: CEO Amir Weiss and EVP Daniell Richard each now own over 20 000 shares, with no unusual trading, while the stock edges higher amid steady market sentiment.

Dr. Michael Chen

09/05/2026, 10:23

3 minutes to read

CRYSVITA Gains Canadian Reimbursement for Adult XLH Patients, Expanding Access Nationwide

CRYSVITA’s new Canadian adult coverage expands access for XLH patients, detailing its FGF23‑blocking mechanism, phase‑III benefits, and provincial reimbursement steps.

Dr. Michael Chen

08/05/2026, 05:01

4 minutes to read

Zoetis Drives Earnings Growth with High‑Value Veterinary Care Innovations

Zoetis thrives as pet owners shift toward high‑value veterinary care, driving strong earnings through innovative antimicrobials, vaccines, and precision diagnostics.

Dr. Michael Chen

04/05/2026, 22:15

5 minutes to read

Incyte Wins FDA Approval for Jakafi XR, Expands Reach with Axatilimab

Incyte’s FDA approval of Jakafi XR—once‑daily ruxolitinib for MPNs and GvHD—offers same efficacy with better adherence, while Australia’s axatilimab expands chronic GvHD options.

Dr. Michael Chen

04/05/2026, 19:26

4 minutes to read

SEC Filing: Natera Officer Sells Shares on Nasdaq – Details & Impact

Read Natera’s latest SEC filing: a senior officer sold shares on May 1, 2026, highlighting the company’s equity‑compensation strategy and its impact on shareholder confidence and corporate governance.

Dr. Michael Chen

04/05/2026, 10:49

3 minutes to read

Recordati’s €11 B Take‑over: How a Rare‑Disease Carve‑Out Could Drive Premium Value

Explore how CVC Capital Partners’ €11 bn bid for Recordati could reshape the Italian pharma’s rare‑disease and core portfolio, unlocking value through a carve‑out and private restructuring.

Dr. Michael Chen

03/05/2026, 21:15

5 minutes to read

Incyte Gains FDA Approval for Once‑Daily Jakafi XR, Expanding Myelofibrosis & GVHD Treatment

Incyte’s new once‑daily Jakafi XR gets FDA approval, offering same efficacy as the twice‑daily drug while easing dosing for myelofibrosis, polycythemia vera, and GVHD patients.

Dr. Michael Chen

03/05/2026, 14:59

3 minutes to read

Grifols SA: Strong Market Gains Backed by Proven Plasma‑Derived Therapies

Grifols SA: steady share growth, plasma‑derived therapies and robust EMA/FDA approvals show the Spanish biopharma firm’s blend of proven efficacy and strategic market positioning.

Dr. Michael Chen

02/05/2026, 12:00

4 minutes to read

Teva Reports Strong Q1 2026 Earnings, $2.4B Cash and $700M Emalex Acquisition

Teva’s Q1 2026 earnings show a 12% cash rise, strategic $700 m Emalex buy‑out, and a $500 m Blackstone‑backed duvakitug push, boosting R&D and niche revenue.

Dr. Michael Chen

01/05/2026, 12:16

2 minutes to read